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THE ROLE OF LORCASERIN IN OBESITY: IDENTIFICATION OF CNS 
TARGETS USING FMRI 
MICHELLE M. CAMP 
ABSTRACT 
With the rapid and alarming rise in the obesity epidemic that continues to 
plague both developed and developing nations, increasing efforts are being 
directed toward solving this pressing issue that is associated with multiple 
metabolic complications. Research efforts continue to target this population for 
greater insight as to causes, preventative measures and treatment options that 
may provide health benefits to those suffering from the physical and 
psychological manifestations of this newly classified neurobiological disease, in 
addition to cut down on excruciating obesity-related costs affecting the current 
health care budget. Alongside an emphasis on physical activity and proper 
nutrition to both prevent and ameliorate the effects of obesity, pharmacological 
treatment has garnered an appreciable appeal as an additional interventional 
approach in an urgency to slow the progression of this widespread problem.  
The introduction of lorcaserin (Belviq®), a serotonin (5-hydroxytryptamine, 
5-HT) agonist that selectively targets the 5-HT receptor subtype 2C (5-HT2C), has 
already exhibited great potential for combating the obesity epidemic since it was 
approved by the Food and Drug Administration (FDA) in 2012. With its ability to 
decrease appetite and enhance weight loss with few side effects, lorcaserin is a 
promising treatment option.  However, the mechanisms behind the drug are still 
	  	  	   vi	  
not fully known. Determining the exact role that lorcaserin plays in appetite 
control would provide valuable insight into appetite regulation and could illustrate 
the medication’s potential for reversing the health-impairing effects of obesity on 
our current populations. 
 This study examined, through the use of functional magnetic resonance 
imaging (fMRI), the effects of lorcaserin on the centers of the brain that control 
appetite and food intake, in addition to areas of cognition that are thought to be 
affected by obesity. Due to the nature of the double-blind trial, only baseline 
characteristics were obtained and analyzed. However, observed correlations 
from these data largely confirm previously established relationships seen in 
obese populations providing support for the validity of this study. These 
correlations were also important to obtain to set the stage for assessing any 
short-term or long-term neuroimaging changes and neurocognitive effects of 
lorcaserin on brain responses to high and low calorie food imagery. 
 
  
 
 
	  	  	   vii	  
 
TABLE OF CONTENTS 
 
TITLE i 
COPYRIGHT PAGE ii 
READER APPROVAL PAGE iii 
ACKNOWLEDGMENTS                iv 
 
ABSTRACT v 
TABLE OF CONTENTS vii 
LIST OF TABLES ix 
LIST OF FIGURES x 
LIST OF ABBREVIATIONS xi 
INTRODUCTION 1 
Obesity Overview                1 
A Closer Look at the Causes of Obesity            4 
Mechanisms of Obesity: Associated Brain Changes          6 
Obesity Effects on Cognition             10 
Targeting 5-HT Receptors            12  
Lorcaserin Emerges as a Treatment Option          14  
Application of Magnetic Resonance           16  
	  	  	   viii	  
Specific Aims              18  
METHODS 21 
Study Overview              21 
Sample Size Justification            21 
Inclusionary Criteria             22 
Exclusionary Criteria             23 
Recruitment and Screening Procedures          27 
Methods after Enrollment            28 
Neurocognitive Testing             33 
RESULTS 35 
Enrollment Numbers and Measured Baseline Data         35 
Correlations               38 
DISCUSSION   40 
APPENDIX                44 	  
REFERENCES               46 
CURRICULUM VITAE 53 
	  	  	   ix	  
LIST OF TABLES 	  
 
Table Title Page 
1 An example of a subject’s schedule during an overnight 
Visit 1 
29 
2 Summary of procedures to be performed through Visit 4 32 
3 Procedures performed for follow up visits 5-12 32 
4 Demographics of subjects that completed Visit 1 in the CRC 35 
5 The baseline measurements to assess neurocognitive 
function 
36 
6 The calculated mean ± SD for all baseline phyiscal 
characteristics collected at Visit 1 
37 
  
 
	  	  	   x	  
LIST OF FIGURES 
 
 
Figure Title Page 
1 Predicted BMI Distribution from 2005 through 2020 2 
2 Estimated years of life lost in a white population as a 
determinant of BMI 
3 
3 Estimated years of life lost in a black population as a 
determinant of BMI 
3 
4 The major projections of orexin and dopaminergic neurons 
in the human brain 
7 
5 The directional interactions between the AMYG, OFG and 
NAc in both hemispheres of the brain 
9 
6 The effects of lorcaserin versus placebo on body weight 15 
7 The mechanisms at work in the production of a BOLD 
signal 
17 
8 Questions from VAS "Pre-Meal & Pre-fMRI #1” 30 
 
 
  
	  	  	   xi	  
LIST OF ABBREVIATIONS 
 
5-HT   5-hydroxytryptamine (Serotonin) 
5-HT2C  5-hydroxytryptamine (Serotonin) Receptor Subtype 2C 
α-MSH  α-melanocortin-stimulating hormone 
AACE   American Association of Clinical Endocrinologists 
ADA   American Diabetes Association  
AE   Adverse Event 
AM   Age Matched 
AMYG  Amygdala 
BMC   Bone Mineral Content 
BMD   Bone Mass Density  
BMI   Body Mass Index 
BOLD   Blood Oxygenation Level Dependent 
CANTAB  Cambridge Neuropsychological Test Automated Battery 
cm   Centimeter 
CNS   Central Nervous System 
CRC   Clinical Research Center 
CRH   Corticotropin-Releasing Hormone 
DBP   Diastolic Blood Pressure 
DEXA   Dual X-Ray Absorptiometry 
DM   Diabetes Mellitus 
	  	  	   xii	  
dL   Deciliter 
DLPFC  Dorsolateral Prefrontal Cortex 
EKG   Electrocardiogram 
FDA   Food and Drug Administration 
fMRI   Functional Magnetic Resonance Imaging 
HbA1c   Glycosylated Hemoglobin 
HTN   Hypertension 
IED   Intra-Extra Dimensional Set Shift 
IFG   Impaired Fasting Glucose 
Kg   Kilogram 
lbs   Pounds 
MAOI   Monoamine Oxidase Inhibitor 
MC4R   Melanocortin-4 Receptor 
Mg   Milligrams 
mmHg  Millimeter of Mercury  
MSSI   Modified Scale for Suicidal Ideation  
NAc   Nucleus Accumbens 
NPY   Neuropeptide Y 
OFC   Orbitofrontal Cortex  
PFC   Prefrontal Cortex 
RMR   Resting Metabolic Rate 
SBP   Systolic Blood Pressure 
	  	  	   xiii	  
SD   Standard Deviation 
SNRI   Serotonin-Norepinephrine Reuptake Inhibitor 
SPSS   Statistical Package for the Social Sciences 
SSP   Spatial Span  
SSRI   Selective Serotonin Reuptake Inhibitor 
SSRT   Stop Signal Reaction Time  
SST   Stop Signal Task  
SWM    Spatial Working Memory  
US   United States 
VAS   Visual Analog Scale  
vmPFC  Ventromedial Prefrontal Cortex 
VRM    Verbal Recognition Memory 
VTA   Ventral Tegmental Area 
WC   Waist Circumference  
WHO   World Health Organization 
YN   Youth Normal  
	  1 
INTRODUCTION 
 
Obesity Overview 
Obesity is an ever-increasing epidemic sweeping the United States (US), 
currently afflicting an estimated 78.6 million adults and accounting for more than 
one-third of the adult population (Ogden et al., 2014). On a broader spectrum, 
according to the World Health Organization (WHO) an estimated 300 million 
people across the globe are obese, with more than 1 billion considered to be 
overweight (Ford & Mokdad, 2008; Waxman & Norum, 2004). A person is 
considered obese due to an excess of adipose, or fat, tissue deposited in varying 
areas of the body ("Obesity: preventing and managing the global epidemic. 
Report of a WHO consultation," 2000). The quantity of adipose tissue that 
renders one obese or overweight is most often determined by the Body Mass 
Index (BMI), which calculates one’s weight (measured in kilograms (kg)) divided 
by one’s height squared (measured in meters (m)). An obese individual is 
characterized as having a BMI ≥ 30, while a person deemed overweight has a 
BMI between 25 and 30. Waist circumference (WC) is another measurement of 
obesity, specifically abdominal or central obesity, which is known as an 
independent predictor of morbidity (("Clinical Guidelines on the Identification, 
Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence 
Report. National Institutes of Health," 1998; Ford & Mokdad, 2008).   
Predictions for the number of American adults that will be obese by 2020 
are anticipated at almost half of the population, with an expected 35% decline in 
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the proportion of the population with a normal weight (Stewart et al., 2009) 
(Figure 1). The percentage of those obese is only expected to rise, with 90% of 
US adults foreseen as overweight by 2030 (Wang et al., 2008). Of those 
currently affected, countless people develop further health complications as a 
result of obesity, including but not limited to cardiovascular disease, stroke and 
type 2 diabetes mellitus (DM), in addition to a decreased life expectancy 
(Fontaine et al., 2003). As depicted in Figures 2 and 3, a clear pattern is 
observed with an increase in BMI as a determinant of number of years of life lost, 
with gender and race taken into account. 
 
Figure 1. Predicted BMI Distribution from 2005 through 2020. Figure taken 
from (Stewart et al., 2009). 
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Figure 2. Estimated years of life lost in a white population as a determinant of BMI. 
Figure taken from (Fontaine et al., 2003).  
 
Figure 3. Estimated years of life lost in a black population as a determinant of BMI. 
Figure taken from (Fontaine et al., 2003).  
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In addition to the health hazards associated with obesity, the costs 
associated with excess weight gain have created a vast economic burden for the 
national health care budget (Wolf & Colditz, 1998). From 1998 to 2008, medical 
expenses related to obesity sky-rocketed from around $78.5 billion to an 
estimated $147 billion, which would account for about 10% of total annual US 
medical expenses at that time (Finkelstein et al., 2009). With these alarming well-
being and financial costs, as well as the knowledge that many of obesity’s 
resulting diseases are leading causes of preventable deaths, it is crucial to 
investigate the causes, as well as methods of prevention and treatment of this 
health crisis that is often rooted in obesity. 
 
A Closer Look at the Causes of Obesity 
It is currently thought that not one, but multiple etiological factors may be 
at play in contributing to the obesity epidemic. Therefore, the causes of obesity 
are not as easily identifiable as one would like to think, as “the mechanisms that 
control fuel homeostasis and adiposity are incompletely understood” (Martinez, 
2000). At first look, obesity appears to be a reflection of poor dietary intake 
choices, which results in a dysfunctional energy metabolism and has the 
potential to be reversed through diet adjustment and exercise (Jauch-Chara & 
Oltmanns, 2014; Webber, 2003). In spite of this deduction, long-term clinical 
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research under this assumption has indicated that obesity is much more 
complex.  
The biggest two elements thought to attribute to excess weight gain are 
one’s genetic makeup and environment, but determining which factor most 
strongly influences obesity can be a challenge. The ‘thrifty gene hypothesis’ as 
proposed by James Neel in the 1960s suggested an evolutionary selective 
survival advantage in populations who constantly encountered starvation, leading 
to a genetic predisposition to efficiently store fat for times of need (Neel, 1962). 
This genotypic hypothesis, which could help explain the obesity problems 
currently facing our society, is supported by the puzzling scenario of the Pima 
Indians, whose shocking obesity rates are not explained through lifestyle, 
environmental or economic factors alone (Bell et al., 2005; Friedman, 2003; 
Howard et al., 1991). Studies looking at families, twins, and adoptions also give 
credence to this notion of a major genetic contribution to obesity (Allison et al., 
1996; Friedman, 2003; Hebebrand & Hinney, 2009). With that said, however, the 
degree of weight gain as a result of genetic disposition may be smaller than we 
think. According to a Great Britain study, environmental factors such as 
socioeconomic status may have a larger impact on weight gain than genetic 
influences (Rennie & Jebb, 2005). Regardless of which factor predominates, 
obesity is thought to develop as a result of the “integration of social, behavioral, 
cultural, physiological, metabolic and genetic factors” ("Clinical Guidelines on the 
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Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--
The Evidence Report. National Institutes of Health," 1998). 
Research has recently shown that “neurocircuits involved in appetite 
regulation are etiologically integrated in the pathomechanism” (Jauch-Chara & 
Oltmanns, 2014). Further, increasing evidence has demonstrated an association 
between psychological manifestations and obesity: “mood disturbances, altered 
reward perception and motivation, [and] addictive behaviors” (Jauch-Chara & 
Oltmanns, 2014). As such, obesity has been progressively classified as a 
neurobiological disease. 
 
Mechanisms of Obesity: Associated Brain Changes 
 In addition to obesity’s metabolic manifestations, repeated and extensive 
studies continue to show that obesity also effects changes in areas of the brain 
involved in feeding behaviors. Although there are numerous brain changes that 
appear to occur, reward processing will be the main focus discussed.  
 Reward processing involves many areas in the brain, from the nucleus 
accumbens (NAc) and ventral pallidum in the ventral striatum, to the ventral 
tegmental area (VTA) in the midbrain (Jauch-Chara & Oltmanns, 2014). Through 
the mesolimbic dopaminergic system activation, the VTA projects to the NAc, 
prefrontal cortex (PFC), hippocampus and amygdala (AMYG) (Figure 4) (Zheng & 
Berthoud, 2007). Dopaminergic projections from the AMYG and PFC to the lateral 
hypothalamus have exhibited direct involvement in food intake regulation (Figure 4) 
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(Baldo & Kelley, 2007). Moreover, when the ventromedial prefrontal cortex 
(vmPFC) or AMYG-hypothalamus projections were interrupted, behavior relating to 
food intake was completely halted, signifying the importance of these connections 
and interactions (Petrovich & Gallagher, 2003; Petrovich et al., 2007). The 
dopamine-rich VTA, also rich in orexin receptors, receives a high volume of orexin 
neuronal activation (an appetite regulator) (Fadel & Deutch, 2002) and plays a role 
in behavioral control associated with food reinforcement (Vittoz et al., 2008; Wise, 
2004). The orexin neurons play “an important role in the cue-induced reinstatement 
of food seeking”, indicating orexin’s crucial role in mediating reward-like behaviors 
(Jauch-Chara & Oltmanns, 2014). 
 
Figure 4. The major projections of orexin and dopaminergic neurons in the human 
brain. The orexin (green) neurons connect with the dopaminergic (red) neurons, which 
are involved in reward processing, via the VTA and hypothalamus. A = amygdala; H = 
hypothalamus; NA = nucleus accumbens, PFC, prefrontal cortex; VTA = ventral 
tegmental area. Figure taken from (Jauch-Chara & Oltmanns, 2014). 
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 Overeating that is associated with obesity has been shown to activate brain 
structures related to reward processing, which in turn activates the mesencephalic 
dopaminergic system, similar activations of which are also seen in addiction-like 
behaviors (Volkow et al., 2008; Volkow & Wise, 2005). Other transmitter systems 
are triggered from this continuous dopaminergic activation, which leads to 
compulsive behavior and inability to exert control over food intake (Volkow et al., 
2008). Data from past studies suggest that high-calorie food stimuli enact a shift in 
the dopaminergic response from homeostatic to rewarding pathways, with 
overeating and obesity as a result (Batterham et al., 2007).  
 In the brain’s reward system, strong anatomical connections exist between 
the NAc, AMYG and orbitofrontal cortex (OFC) (Figure 5) (Berridge & Kringelbach, 
2008; Heimer & Van Hoesen, 2006; Stoeckel et al., 2009). Studies looking at brain 
changes in obese as compared to lean female populations have noted abnormal 
activity and connectivity of the AMYG, NAc and OFC in the former while both 
groups viewed high and low calorie food images (DelParigi et al., 2004; Stoeckel et 
al., 2008). Further analysis showed increased connectivity between the OFC and 
NAc, but decreased connectivity with the AMYG activating either OFC or NAc 
(Stoeckel et al., 2009). The former connectivity may be linked to a greater drive 
to eat in the presence of a food cue, whereas the latter could be associated with 
“suboptimal modulation of the affective/emotional aspects of a food's reward 
value or an associated cue's motivational salience” (Stoeckel et al., 2009). This 
suggests that obese populations may have not only a greater activation of the 
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reward system, but also differing regional interactions within the network affecting 
their food valuations.  
 
Figure 5. The directional interactions between the AMYG, OFG and NAc in both 
hemispheres of the brain. Figure taken from (Stoeckel et al., 2009). 
 
 Another finding showed that, in lean participants, dorsolateral prefrontal 
cortex (DLPFC) deactivation by transcranial magnetic stimulation resulted in 
decreased valuations of real food stimuli, proposing that, at the time of food 
consumption, the DLPFC helps make valuation choices (Camus et al., 2009).  
Further, DLPFC activity also appeared to increase as subjects who were dieting 
demonstrated self-control toward food choices based on health and taste through 
modulation of the vmPFC (Hare et al., 2009). Through these studies and other 
comprehensive research findings, we find substantial evidence that obesity has 
significant effects on the brain, giving credence to its classification as a 
neurobiological disease. Continuing to investigate these effects and interactions 
among the myriad cerebral networks would certainly elucidate more mechanisms 
underlying the changes seen in the brain of an obese person.  
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Obesity Effects on Cognition 
In addition to affecting feeding behaviors in the brain, obesity has also 
shown indications of altering sophisticated cognitive processes. During 
neuropsychological tasks integral to executive functioning, working memory and 
cognitive control, obese patients have illustrated impaired cognition in their 
performance (Batterink et al., 2010; Boeka & Lokken, 2008; Hendrick et al., 
2012). For example, in the stop signal task (SST), a higher overweight 
percentage correlates with the stop signal reaction time (SSRT), which measures 
inhibitory control (Nederkoorn et al., 2007). A longer SSRT indicates that it takes 
a subject more time to inhibit a response, and therefore, he or she has poorer 
response inhibition (Nederkoorn et al., 2007). fMRI studies have shown that more 
impulsive subjects exhibit diminished brain activity in the widespread regions of 
inhibitory control centers (Batterink et al., 2010). Therefore, the greater one’s 
impulsivity, as associated with a longer SSRT, the more difficult it may be to lose 
weight (Logan, 1997; Nederkoorn et al., 2007). Obese individuals, especially 
obese binge eaters, tend to be more impulsive than lean individuals, which could 
be due to this decrease in inhibitory brain activation areas, and possibly act as a 
hindrance to weight loss treatment (Davis et al., 2004; Ryden et al., 2003). In a 
study comparing lean and obese females, Hendrick demonstrates that obese 
females exhibit diminished brain activity in cortical areas such as the insula, 
inferior parietal cortex and supplementary motor area in the stop as compared to 
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go trials of SST (Hendrick et al., 2012). Further, brain activation in these same 
areas inversely correlated with BMI (Hendrick et al., 2012).  
These cognitive aspects of obesity are of particular interest to academic 
researchers, for evidence shows that weight loss and the reversal of 
physiological manifestations associated with obesity have been shown to 
improve cognitive abilities. Obese subjects who had undergone gastric bypass 
surgery and lost weight as a result demonstrated this improvement by exhibiting 
a decrease in brain activity to high-calorie foods in reward centers of the brain 
(Ochner et al., 2011). Additionally, non-food tasks administered to obese 
participants after bariatric surgery and ensuing weight loss also exhibited 
cognitive improvements (Gunstad et al., 2011). Moreover, another study 
discovered that obese women who dieted and lost weight showed significant 
improvement in word recall performance (Kretsch et al., 1997). These examples 
argue in favor of the hypothesis that cognitive deficits associated with obesity 
may, in fact, be related to the reward processing and cognitive control centers, 
both integral to the mechanisms behind food processing. Further, these studies 
suggest the potential of improvement and reversal of cognitive abilities through 
weight loss.   
Obesity’s prevalence and metabolic ramifications continue to demand new 
and more effective treatment options. Of course, a healthy diet, inclusive of 
varying food groups and a proper macronutrient breakdown of carbohydrates, 
proteins and fats is thought to promote a healthy weight and lifestyle with many 
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preventative and protective effects. Additionally, physical activity, no matter how 
brief or light, has been shown to increase energy expenditure in combating and 
preventing obesity. However, with an obesity trend increasing exponentially in 
both developed and underdeveloped countries, the scientific community is 
continually beckoned to delve further into other possible causes of obesity and 
seek alternate treatment options to slow and possibly reverse the rapid rise in the 
overweight phenomena.  
 
Targeting 5-HT Receptors 
5-HT is an evolutionarily ancient neurotransmitter within the central 
nervous system (CNS) that has many roles in the body, acting through at least 
14 types of receptors widely dispersed in the body (Puig & Gener, 2015; 
Thomsen et al., 2008). Serotonergic neuronal axons in the brain innervate almost 
every structure in the brain, playing a vital role in mediating numerous brain 
functions such as “sensory processing, cognition, mood, autonomic responses, 
and motor activity” (Puig & Gener, 2015). One of 5-HT’s crucial functions is 
thought to act via activation of the 5-HT2 receptors in the neural satiety pathway, 
which is activated after caloric intake to cause hypophagia (Halford et al., 2011). 
Therefore, this subset of 5-HT receptors was deemed a hopeful target for anti-
obesity medications, and many serotonergic agonists were developed as a 
result. Previously used agonists, such as fenfluramine and dexfenfluramine, 
displayed initial promise with effective weight loss seen in subjects taking the 
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medication (Halford et al., 2011; Heisler et al., 2002). However, many people 
also began to develop serotonin-related valvulopathy, a severe form of heart 
disease, and the medications were immediately banned from distribution 
(Garber, 2015).  
Scientists addressed the shortcomings as to why the medications had 
failed and began to investigate how to improve the obesity medication as to avoid 
harmful side effects while retaining the effective appetite-suppressing aspects. 
Research honed in on the differing subtypes of 5-HT2 receptors for an answer. 
The failure of serotonergic agonists like fenfluramine and dexfenfluramine lay in 
their non-selective targeting of 5-HT2 receptors, which included 5-HT2A and 5-
HT2B subtypes that are densely found on cardiac muscle and whose repeated 
activation can result in valvular heart disease (Loke et al., 2002; Smith et al., 
2010). Through use of a 5-HT2C antagonist, it was determined that the weight 
reducing effect of fenfluramine could be blocked (Vickers et al., 2001). Therefore, 
a selective 5-HT2C agonist could provide an anti-obesity benefit while 
simultaneously avoiding any adverse cardiac events (Vickers et al., 2001). An 
experiment with knock-out mice for the 5-HT2C receptors exhibited mice with 
increased food intake and higher body weight as a result, confirming that this 
selective receptor did, in fact, play in a part in obesity (Tecott et al., 1995). The 
study observed changes in the mice hormone levels, particularly leptin and insulin, 
as well as increases in meal duration and frequency (Nonogaki et al., 1998; Tecott 
et al., 1995). This led to the birth of the 5-HT2C agonist lorcaserin. 
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Lorcaserin Emerges as a Treatment Option 
Continuing pharmacological research efforts have increasingly focused on 
lorcaserin, a selective 5-HT2C receptor agonist, as an efficacious and safe 
treatment option, in conjunction with diet and exercise, for those struggling with 
obesity and its many consequential effects. 
The 5-HT2C receptors that lorcaserin acts on are found almost entirely in 
the CNS, including areas like the thalamus and hypothalamus, where both 
regulate feeding, as well as in more cortical areas that regulate higher thought 
and top-down processes (Abramowski et al., 1995). Activation of these receptors, 
particularly in the hypothalamus, triggers a cascade that begins with release of α-
melanocortin-stimulating hormone (α –MSH) and, in turn, regulates appetite via 
melanocortin-4 receptors (MC4Rs) (Heisler et al., 2002; Lam et al., 2008). 
Though not fully elucidated, it is presumed that this MC4R pathway activation is 
responsible for stimulating the cortical areas, noted by these receptors acting in 
the cortex to decrease food intake (Benoit et al., 2000).  
According to a 1989 study, the NAc, OFC and AMYG of the reward system, 
areas where aforementioned connectivity seems to be altered in obese 
populations, are also spaces which appear to have 5-HT2C receptors (in original 
terminology the 5-HT1C receptor) in rodents (Hoffman & Mezey, 1989). This 
possibility would be of particular interest in determining lorcaserin’s effects in the 
CNS.   
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Since the approval of lorcaserin by the Federal Drug Administration (FDA) 
in June 2012, clinicians have increasingly administered the medication for 
purposes of treating obesity due to its ability to suppress appetite and enhance 
weight loss (Smith et al., 2010). Currently, lorcaserin has proven effective in 
weight loss treatment, with an average of greater than 5% total body mass loss 
(Figure 6) (Fidler et al., 2011; O'Neil et al., 2012; Smith et al., 2010). Additionally, 
after one year of treatment with lorcaserin, fasting glucose, insulin and 
glycosylated hemoglobin (HbA1c) levels were significantly reduced as compared 
with placebo treatment (Smith et al., 2010).  
 
 
Figure 6. The effects of lorcaserin versus placebo on body weight. The percentage 
of patients who lost more than 5% and 10% of their baseline body weight, respectively, 
at the end of year 1. Figure taken from (Smith et al., 2010). 	  	  
Side effects are low-risk with regards to a medication in general. In the 
multi-centered, placebo-controlled lorcaserin trial, the most commonly reported 
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adverse events (AEs) were “headache, upper respiratory tract infection, nausea, 
dizziness, sinusitis, and nasopharyngitis”  (Garber, 2015).  
Therefore, while there has been much success with the medication 
through animal studies and human trials, little has been deciphered as to the 
mechanisms underlying the medication’s potential. 
 
Application of Magnetic Resonance  
fMRI, a non-invasive technique that is heavily utilized today in research of 
brain function and diagnosis of disease, is the result of more than a century’s 
worth of application and integration of novel and established concepts, ranging 
from aspects of blood flow to the magnetic properties under which an fMRI scan 
operates (Raichle, 2009). 
fMRI generates its imagery from an blood oxygen level dependent (BOLD) 
signal, which indirectly measures neuronal activity and converts these responses 
into images of the brain (Arthurs & Boniface, 2002). An overview of the pathway 
that generates a BOLD signal is represented in Figure 7. The BOLD response 
can vary depending on artifacts such as head motion and field in-homogeneities 
like cranial implants, which can alter how much the BOLD signal accurately 
reflects a particular hemodynamic response and make it difficult to quantify a 
reliable response (Arthurs & Boniface, 2002). 
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Figure 7. The mechanisms at work in the production of a BOLD signal. Many steps 
are involved in the pathway to generating an fMRI BOLD response. A stimulus or 
modulation in background activity triggers a chain reaction that alters neuronal activity 
(1), inducing complex neurovascular coupling (2) that incites a hemodynamic response 
(3). It is this change in hemodynamics that the fMRI detects and converts into BOLD 
imagery (4). EPI = Echo Planar Imaging. Figure taken from (Arthurs & Boniface, 2002). 
 
Research studies and clinical practices have increasingly turned to fMRI 
for assessment and analysis of brain activity due to its high spatial resolution and 
non-invasive manner of measuring a change in blood flow and metabolism, 
including oxygen consumption and glucose utilization (Raichle, 2009). Over the 
past two decades, this powerful fMRI tool has shed light on many neurological 
functions and insights into how our brain reacts to different tasks and emotions, 
and how changes in those respects can alter brain processing and function. Due 
to BOLD contrast, the fMRI “has grown in usage, sophistication, range of 
applications, and impact” in the flourishing field of neurology and continues to 
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show promise in discerning many unsolved questions of the brain (Bandettini, 
2012).  
The extraordinary potential of fMRI in the future of brain mapping and 
function makes this an essential tool in studying the effects of lorcaserin on the 
brain, the only domain where 5-HT2C receptors are thought to be located. 
No prior studies have examined the neural mechanisms underlying lorcaserin’s 
effects on 5-HT2C receptors, and thus, no data is currently available on how 
lorcaserin changes the way the brain looks at food images with fMRI. Studying 
these effects will help identify human CNS targets for lorcaserin that may alter 
eating behavior.   
 
Specific Aims  
This project aims to further study and understand the role of lorcaserin in 
obesity and its effect on CNS targets. Specifically:  
1. To examine lorcaserin’s effect on the CNS and impact on food 
visualization through use of fMRI.  
Hypothesis 1a: After lorcaserin treatment, subjects will activate brain areas 
involved in cognitive control and decrease activation in reward-related regions 
during food visualization. Specifically, we hypothesize that lorcaserin 
administration will result in higher activity in lateral aspects of the PFC and 
anterior cingulate cortex, and lower activity in the insular cortex, medial OFC and 
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striatum, which previous studies in humans have linked to hedonic aspects of 
eating, food cravings and eating disinhibition.  
Hypothesis 1b: After lorcaserin treatment, subjects will enhance performance in 
neuropsychological tasks that assess executive function, specifically inhibitory 
control, reward-based decision-making, rule acquisition and reversal and working 
memory. We also hypothesize that improvement in neuropsychological 
performance will be associated with increased fMRI activation in cognitive control 
areas during food visualization. 
2. To assess lorcaserin’s satiety and weight reducing effect through 
physiological measurements, as well as any association with 
changes in fMRI responses and neuropsychological performance.  
Hypothesis: Lorcaserin will alter physiological parameters related to energy 
homeostasis such as hunger level and percentage body fat. Beneficial effects will 
be correlated with increases in fMRI activation in cognitive control areas, 
decrease in reward-related regions and increased performance in 
neuropsychological tasks. 
3. To analyze whether the long-term weight reducing effects of 
lorcaserin can be predicted by early food visualization. 
Hypothesis: Those who were able to lose and maintain more percentage weight 
loss in the long term (through a year) will show increased brain activation in 
	  20 
cognitive control areas and decreased reward-related regions in the early fMRI 
studies. 
It is anticipated that this research study will only enhance the support of 
using lorcaserin as an effective tool for obesity treatment and that it emphasizes 
the importance of determining the CNS targets of the medication lorcaserin and 
investigating whether this 5-HT2C agonist has downstream metabolic effects. It is 
hoped that, through this study, participants may benefit from the clinically proven 
efficacy of lorcaserin as a treatment of obesity, as both a means of access to this 
medication free of charge, in addition to the health benefits that lorcaserin that 
may provide.  
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METHODS 
 
Study Overview 
 
 In order to carry out this study, subjects were enrolled in a randomized, 
placebo-controlled manner to ensure the greatest accuracy in determining the 
effects of lorcaserin. Forty subjects were recruited for enrollment, half (n=20) of 
which were randomized to receive treatment of either lorcaserin or placebo. The 
pharmacy supplying the treatment was the only source not blinded as to whether 
placebo or lorcaserin was administered. The randomization further attempted to 
block for gender in hopes for equal enrollment numbers of men and women. 
Each subject took one tablet of lorcaserin 10 mg or placebo twice a day, once in 
the morning and once in the evening. The treatment could be accompanied with 
or without a meal.  
 
Sample Size Justification 
 Because no prior studies with respect to the mechanisms of lorcaserin 
have been done, this pilot study was performed to obtain pilot data from which a 
sample size could be calculated for future, larger studies investigating lorcaserin. 
In theory, up to 200 subjects needed to be screened in order to recruit the 
desired 40 subjects. Subjects that drop out due to various reasons, like 
intolerance or any other reason that would not allow a subject to continue to 
participate in the study, were replaced. To account for a potential 25% dropout 
rate, up to 5 additional participants per group were recruited, which would 
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provide full data sets to be assessed on at least 15 people in each treatment 
group.  
Due to a current, unpublished study that looks at effect size changes in 
the hypothalamus with pharmacological intervention, a mean difference of 0.74 
and a standard deviation (SD) of 0.5 can be used yielding an effect size of 1.52. 
Thus, assuming this change in brain activation, 99% power with two groups of 20 
can be calculated. Otherwise, with 80% power and two groups of 20 participants, 
an effect size of 0.9 can be detected. 
Pearson correlation coefficients were run on baseline data using Statistical 
Package for the Social Sciences (SPSS) software. Results were shown using r 
and p values. The remainder of data will be analyzed in the same manner. 
Analysis of fMRI data will run concurrently with the study to ensure significant 
findings, and power analyses will be redone as results are updated to ensure a 
reasonable number of participants in the final cohort. 
 
Inclusionary Criteria 
The minimum inclusionary criteria required, first and foremost, a subject to 
be obese, as previously defined of having a BMI of at least 30 kg/m2. 
Additionally, a subject could have had a BMI of greater than 27 kg/m2 if they had 
comorbidities, such as high blood pressure, high cholesterol or pre-diabetes, 
which is defined by the American Diabetes Association as having a laboratory-
confirmed HbA1c count in the range of 5.7 – 6.4 %, or impaired fasting glucose 
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(IFG) level of 100 – 125 mg/dL as determined by the American Association of 
Clinical Endocrinologists (AACE) (Garber, 2015). If a subject had high blood 
pressure and/or high cholesterol, they must have been controlling the high levels 
with medication to be eligible to participate. Additionally, the age range of 
suitable candidates was between 18 and 65 years. Lastly, this study required 
participants to be able to read, speak and understand English, for the importance 
and necessity of each subject’s comprehension of the study’s many facets, in 
addition to the neurocognitive tests that involved word recall tasks. 
 
Exclusionary Criteria 
Numerous conditions and pathologies, as pertaining to the study’s design, 
led to participant exclusion. Additionally, it was crucial to remove any possible 
sources of confounding results. Subjects who, although obese, were otherwise 
healthy were sought.  
The first exclusionary criterion for this study was the presence of DM in 
order to decrease variability of our subject population, as the brains of diabetic 
participants could appear differently when using fMRI due to possible cerebral 
atrophy (Lunetta et al., 1994). Other significant exclusionary criteria involved 
multiple factors associated with weight loss: current participation in other weight 
loss studies; history of a gastric bypass or other related weight loss surgery; and 
use of weight loss medication.  
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 Specific disease states and medications were grounds for not including 
certain subjects. For the aforementioned safety reasons in the introduction, those 
with any heart valve problems were not eligible to participate. Due to potential 
adverse drug interactions that could increase the risk of developing 5-HT 
syndrome, the following medications precluded one’s ability to become enrolled: 
selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine 
reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), triptans, 
bupropion, and St. John’s Wort. Many of these exclusionary medications are 
used to treat subjects suffering from illnesses such as depression, bipolar 
disorder, schizophrenia, anxiety and migraines. A history of depression could 
also disqualify a subject, which stemmed from past trials of at least a year in 
length where depression/mood problems were reported in 2.6% lorcaserin-
treated subjects versus 2.4% placebo-treated subjects. Suicidal ideation was 
reported in 0.6% lorcaserin-treated subjects versus 0.4% placebo-treated 
subjects. Accounting for this 2 per 1000 patient difference, and the fact that a 
history of depression could increase the possibility of becoming depressed once 
more, we sought to eliminate these risks completely through exclusion.  
Another exclusionary criterion included women who were either pregnant 
or had plans to become pregnant within the next year, due to the appetite-
suppressing nature of lorcaserin and the ensuing harm this could impart on a 
fetus. As a safety measure, therefore, at each screening visit and subsequent 
enrolled visit, women had to agree to provide urine for a pregnancy test 
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measuring human chorionic gonadotropin to confirm that they were not pregnant. 
If a woman became pregnant at any point during her participation, she was 
immediately withdrawn from the study. For similar appetite-suppressing 
characteristics of the medication, those with a history of an eating disorder such 
as anorexia or bulimia were additionally excluded.  
There were additional exclusionary factors with respect to the fMRI 
machine. Participants with metallic implants or tattoos were subject to exclusion 
due to the possibility of the strong magnet displacing the metal. Those with MRI-
safe metal implants were excluded on a case-by-case basis, dependent on 
whether the implants might produce potential artifacts that would hinder the most 
desirable fMRI experimental results, and in turn, an analysis of lorcaserin’s 
effects in the brain (Krupa & Bekiesinska-Figatowska, 2015). For example, metal 
screws in one’s leg would not disqualify a subject, whereas dental fillings, 
especially in the upper jaw, would likely lead to the exclusion of a participant. 
Other implants, such as bioimplants with magnetic activation like cochlear 
implants or pacemakers excluded subjects from participating for their own safety. 
We disqualified inquiring subjects with claustrophobia, as we did not wish to 
induce anxiety that could be attributed to the confined spaces in this research 
fMRI machine, whose larger research magnet resulted in an even smaller space 
than normal. The research magnet’s scanning table had an upper limit for body 
weight of 330 pounds (lbs) or 150 kg that could preclude one’s participation. With 
a scan diameter of 30 cm, body dimensions could also become problematic with 
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respect to patient comfort as well as the performance quality of the scan. 
Therefore, those with a shoulder or hip width close to or greater than that 
diameter were subject to exclusion. 
Subjects with epilepsy, especially photosensitive epilepsy, were excluded 
to prevent any unnecessary AEs or episodes triggered by visual stimulation 
amidst viewing food images. Vegetarians and vegans were cause for elimination 
from the study due to potential bias or differing brain responses to various animal 
or animal-product food images that they would be asked to view in each fMRI 
session. 
For purposes of ensuring results with the fewest number of confounding 
variables, other exclusionary criteria included subjects with: uncontrolled 
infectious diseases, such as HIV or hepatitis; uncontrolled endocrine conditions, 
such as Cushing’s or acromegaly; untreated thyroid disease; anemia with a 
hemoglobin count <10; any history of cancer or lymphoma; inflammatory 
conditions like inflammatory bowel disease or rheumatoid arthritis; a current 
usage of illicit drugs; moderate to severe kidney and/or hepatic impairment; a 
current usage of blood thinners (except aspirin); and a history of a stroke, heart 
failure or heart attack. For more information on patient safety with respect to 
taking lorcaserin, please see Appendix 1. 
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Recruitment and Screening Procedures 
In order to recruit participants, the study was advertised in newspapers, on 
the Internet, in local hospitals, at public transportation stops, and in numerous 
other local establishments, providing interested candidates with our contact 
information to inquire about the study. 
A preliminary screening was conducted over the phone with all subjects, 
first explaining an overview of the study, then asking a series of questions related 
to their medical history to assess whether they would qualify for an in-patient 
screening. If a subject were an eligible candidate, he or she was brought in for 
further procedures and examinations at an in-patient screening. The subjects 
arrived having fasted for twelve hours prior to their visit. A co-investigator of the 
team read through an informed consent form with each potential subject, 
explaining the study in more detail and emphasizing each subject’s voluntariness 
and ensuring patient confidentiality throughout the entire process. If the subject 
chose to sign the form with a team member as a witness, the screening visit 
proceeded as follows. Nurses measured each subject’s height and weight to 
confirm the BMI requirement, documented vital signs, and drew blood for 
laboratory testing of various markers and hormones. Each blood draw most 
specifically assessed adequate liver and kidney function, confirmed the absence 
of DM from HbA1c and IFG levels, and ensured other blood counts were normal 
before official enrollment. Additionally, the nurses administered an 
electrocardiogram (EKG) to assess cardiac function. Abnormal EKG results, such 
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as bradycardia or tachycardia, led to exclusion from the study. A dietician 
recorded anthropometric measurements for to ensure a potential participant 
would properly fit into the fMRI machine. A physician obtained a thorough 
medical history and performed a physical exam, but first asked subjects 
questions from the Modified Scale for Suicidal Ideation (MSSI) to make certain 
that a given subject was not currently depressed in any manner. If subjects 
scored any number greater than 0 (overall score ranged from 0 to 54), indicative 
of no depression, they were immediately excluded from enrollment consideration 
or discontinued if already being treated. When subjects completed all the 
aforementioned procedures at a screening visit and their overall health 
parameters fell within the comprehensive inclusionary criteria, we officially 
enrolled them in our study.  
 
Methods after Enrollment 
Upon enrollment into the yearlong study, a subject committed to three 
overnight visits (visits 1, 2 and 4) to the Clinical Research Center (CRC) at Beth 
Israel Deaconess Medical Center and one short morning visit (visit 3) all during 
the first month. An overview of an hourly schedule at a given overnight visit is 
outlined in Table 1.  Follow-up morning visits (visits 5 - 12) occurred once a 
month up until six months, after which they continued once every other month for 
the remainder of the year. Additionally, from six months onward, every subject 
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was administered lorcaserin regardless of whether he or she was randomized to 
receive the medication at the start.  
Table 1. An example of a subject’s schedule during an overnight Visit 1. 
Visit 1 - First dose of lorcaserin and baseline fMRI 
Day 1+\- 2 days 
5:00 PM Subjects report to the CRC for an overnight stay 
Pregnancy test (women only) 
9:00 PM Standardized meal (without coffee) provided by CRC nurse 
Day 2+\- 2 days 
8:00 AM Resting Metabolic Rate 
Anthropometry 
9:00 AM Meet with dietician 
9:45 AM Blood tests: Safety labs, adipokines, hormonal labs, gut hormones, 
metabolic labs 
Vitals 
Medical History Review, Physical Exam, and distribution of food diaries 
10:00 AM Hunger assessment via VAS pre-fasting fMRI 
“fasting” fMRI scan (45 min) 
11:00 AM Hunger Assessment via Visual Analog Scale (VAS) post-fasting fMRI 
Standardized meal (without coffee) provided by CRC nurse (30 min) 
12:00 PM Hunger assessment via VAS post-meal and pre-fed fMRI 
“fed” fMRI scan (45 min) 
1:00 PM Neuropsychological testing 
2:00 PM DEXA scan 
2:30 PM           Patient takes first dose of lorcaserin or placebo and stay for 30 minute              
observation 
 
As observed in Table 1, each subject was asked to sleep overnight in the 
CRC in order to control for his or her environment, as well as fasting states, 
leading up to the fMRI scans. The morning after each overnight stay, each 
participant was expected to complete two forty-five minute fMRI sessions, during 
which the participants were asked to view food and non-food images and to 
press a button corresponding to whether they could visualize the image or not. 
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The images ranged from rocks and pencils in the non-food slides to high-protein 
and high-fat imagery in the food pictures. The first scan measured the brain 
during the fasting state and the second scan measured the brain during the fed 
state. The nursing staff provided each participant with a standardized meal 
between the two scans. A baseline fMRI scan of each state was carried out 
before the administration of placebo or lorcaserin, and remaining scans took 
place one week and four weeks after initiation of treatment. In conjunction with 
the fMRI scans, participants were asked to indicate on a scale of 0 – 100, 
through use of a Visual Analog Scale (VAS), five parameters to assess hunger 
and fullness at three time points: fasting pre-fMRI, fasting post-fMRI, and fed pre-
fMRI, respectively (Figure 8). 
 
 
Figure 8. Questions from VAS "Pre-Meal & Pre-fMRI #1.” Answers were self-reported 
by subjects by marking an “X” on the line, where a mark at the very left indicated 0 and 
that at the far right signified 100.  
 
Another measurement at visits 1 and 4 that accompanied the fMRI scans 
included a Dual Energy X-Ray Absorptiometry (DEXA) scan, which assessed 
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bone density, lean mass and fat mass (Table 2). Each subject’s resting metabolic 
rate (RMR) was measured at these visits. Both parameters were additionally 
measured without the fMRI facet at the midpoint and conclusion of study 
participation during visits 9 and 12, respectively (Table 3).  
As the treatment was not administered to the subject until the end of visit 
1, all visit 1 procedures assessed baseline measurements. In addition to the 
administered treatment, each subject was sent home with food diaries to record 
food/drink consumption and VAS forms to assess hunger. Subjects were asked 
to complete these forms three times between each visit, twice on weekdays and 
once on a weekend day.  
As summarized in Tables 2 and 3, vitals were taken, blood was drawn and 
anthropometry was measured at each visit 1 – 12. Additionally during these 
visits, each subject met with a dietician to discuss eating habits and a physician 
for a routine physical and medical history. The physician took note of any newly 
presenting side effects.  
Compensation for participation was offered, as well as reimbursement for 
travel expenses for the duration of the study, except for the screening visit. A 
review of all outlined procedures at each visit is referenced in Tables 2 and 3. 
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Table 2. Summary of procedures to be performed through Visit 4. 
 
Visit Number 0 1  2  3  4  
Visit Timing Screening Day 1-2 Day 8-9 
Day 16 
+\- 2 days Day 29-30 
PROCEDURES           
Informed Consent x         
Blood Draw x x x X x 
Vitals x x x X x 
Anthropometry x x x X x 
Pregnancy Test x x x X x 
EKG x         
Medical History x x x X x 
Physical Exam x x  x X  x 
DEXA & RMR   x     x 
Hunger Assessment VAS   x x    x 
fMRI    x x    x 
Mock fMRI   x       
Neuropsychological 
Testing   x x   x 
 
 
Table 3. Procedures performed for follow up visits 5-12. 
Visit Number 5,6,7,8,10,11 9, 12 
Visit Timing Month 2-10 Month 6, 12 
Procedures     
Blood Draw x X 
Vitals x X 
Anthropometry x X 
RMR  X 
Pregnancy Test x  
Medical History x X 
Physical Exam  X 
DEXA  X 
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Neurocognitive Testing 
An important task to accompany the fMRI scans included neurocognitive 
testing, also known as Cambridge Neurocognitive Testing Automated Battery 
(CANTAB), which was used to assess general mental function. A research 
member administered the following exercises to each participant at visits 1, 2 and 
4:  
Stop-Signal Task (SST): The SST is a classic behavioral inhibition test, 
which uses a staircase procedure to generate an estimate of the stop signal 
reaction time, which measures an individual’s ability to inhibit a prepotent 
response. The subject is told to press the buttons on the press pad when they 
see the go signal (arrow), but, if they hear an auditory stop signal (a beep), they 
should withhold their response and not press the button.  
Intra-Extra Dimensional Set Shift (IED): The IED is a test of rule 
acquisition and reversal. It featured visual discrimination and attentional set 
formation, as well as maintenance, shifting and flexibility of attention. The subject 
started by seeing two shapes, and had to learn which one was correct by 
touching it. Feedback would teach the subject which stimulus was correct, and 
eventually, the stimuli and/or rules were changed. These shifts were initially intra-
dimensional, then later extra-dimensional. Subjects progressed through the test 
by satisfying a set criterion of learning at each stage.  
Verbal Recognition Memory (VRM): The VRM test assessed immediate 
and delayed memory of verbal information under free recall and forced choice 
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recognition conditions, in order to provide comparable results. Subjects read a 
list of words and then proceeded through free recall (producing the words) and 
recognition (choosing from a list) phases, and following a delay, they proceeded 
through a delayed recognition phase. 
Spatial Span (SSP): The SSP test assessed working memory capacity as 
a measure of frontal lobe function. Subjects observed a set of white boxes, some 
of which changed color, one by one, in differing sequences. When a tone 
signaled each sequence had ended, subjects were prompted to touch each box 
that had changed color, in the same order as presented. The number of boxes in 
each sequence increased incrementally from 2 to ultimately 9. At each level, the 
subject had three attempts to pass the sequence.   
Spatial Working Memory (SWM): The SWM is a self-ordered task that 
assessed a subject’s ability to retain spatial information, to manipulate 
remembered items in working memory, and to strategize heuristically. This test 
acted as a sensitive measure of the frontal lobe and associated executive 
function. Subjects were presented with colored boxes, one of which contained a 
blue token that could be revealed by touching each box in a search and after 
placed in the right column (Figure 8). The subject then began the search anew: 
the blue token was hidden in each box only once, so the subject was directed to 
not return to those boxes where a blue token had already been found.  
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RESULTS 
 
Enrollment Numbers and Measured Baseline Data 
 
Over the phone, 372 subjects were successfully screened, 258 of whom 
failed the screening according to the protocol and 112 of whom passed 
preliminarily. Of the 112 potential subjects that passed, 63 completed an in-
patient screening visit at the CRC. Excluding those who did not meet the 
inclusion criteria, thus far 38 subjects have been enrolled into the study, some of 
whom will begin their visits in the coming weeks and months. Baseline results 
have been obtained on all 24 subjects who have completed their visit 1. A 
summary of basic demographics are summarized in Table 4. The subjects’ ages 
ranged from 26 to 64 years, and approximately equal numbers of gender and 
race were recruited. Table 5 displays the baseline results for neurocognitive 
assessment of each subject, while Table 6 exhibits the mean ± SD for each 
measured physical health characteristic. 
   
Table 4. Demographics of subjects that completed Visit 1 in the CRC. 
Demographics 
Age (years) 50.05 ± 12.45 
Females n=13 
Males n=11 
Race (white) 54% 
Race (black) 46% 
Ethnicity (Hispanic) 8% 
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Table 5. The baseline measurements to assess neurocognitive function. RT = 
Reaction Time; SSD = Stop signal delay; SSRT = Stop signal reaction time. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CANTAB Results 
Intra-Extra Dimensional Set Shift (IED) Baseline Value  
(mean ± SE) 
Total Errors (adjusted)  46.26 ± 61.16 
Stages Completed 7.74 ± 2.45 
Spatial Span (SSP)    
Span Length 5.82 ± 1.22 
Stop Signal Task (SST)    
Direction errors on stop and go tasks  2.70 ± 3.20 
Proportion of successful stops (last half)  0.54 ± 0.12 
Median correct RT and GO trials 504.65 ± 152.03 
SSD (50%)(Last half)  311.71 ± 168.52 
SSRT (Last half)  192.94 ± 114.88 
Spatial Working Memory (SWM)   
Between Errors 47.00 ± 20.94 
Strategy  28.45 ± 5.12 
Verbal Recognition Memory (VRM)    
Free recall: total correct (immediate) 6.52 ± 2.69 
Free recall: total novel words (immediate) 0.30 ± 0.70 
Recognition: total correct (immediate) 23.17 ± 1.37 
Recognition: total false positives (immediate) 0.09 ± 0.29 
Recognition: total correct (delayed) 22.87 ± 1.91 
Recognition: total false positives (delayed) 0.13 ± 0.34 
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Table 6. The calculated mean ± SD for all baseline phyiscal characteristics 
collected at Visit 1. ALT = Alanine aminotransferase; ApoA-1 = Apolipoprotein A-1; 
ApoB = Apolipoprotein B; aPTT = Activated partial thromboplastin time;  AST = 
Aspartate aminotransferase; BMI = Body Mass Index; GGT = Gamma-glutamyl 
transferase; HDL = High-density lipoprotein; INR = International normalized ratio; IU = 
International unit;  LDL = Low-density lipoprotein; RBC = Red blood cells; VCO2 = Rate 
of elimination of carbon dioxide; VLDL = Very low-density lipoprotein; VO2 = Maximum 
absolute oxygen consumption; VO2/kg = Maximum relative oxygen consumption; WBC 
= White blood cells; WC = Waist Circumference 
Physical Health Characteristics Baseline Value  
(mean ± SD) 
Body Temperature 98.14 ± 0.34 
Systolic Blood Pressure (SBP) sitting (mmHg) 124.13 ± 15.76 
Diastolic Blood Pressure (DBP) sitting (mmHg) 75.92 ± 9.83 
Heart Rate (beats/minute) 77.13 ± 12.43 
Respiratory Rate (breaths/minute) 16.25 ± 2.31 
VO2 (L/min) 1.24 ± 4.74 
VO2/kg (mL/kg/min) 2.38 ± 0.41 
VCO2 (L/min) 0.20 ± 0.03 
24 hour urinary nitrogen (g/d) 13 ± 0 
Respiratory Quotient (RQ) 0.82 ± 0.04 
Measured Resting Energy Expenditure (REE) 1711.13 ± 268.03 
Predicted Basal Metabolic Rate (BMR) 1855.48 ± 264.29 
ANTHROPOMETRY   
Body Composition Results   
WC (average of 3): iliac (cm) 122.38 ± 15.60 
WC (average of 3): smallest (cm) 121.13 ± 13.75 
WC (average of 3): broadest hip (cm) 123.62 ± 16.27 
Height (cm) 169.42 ± 8.70 
Weight (kg) 106.27 ± 18.60 
BMI (kg/m2) 37.05 ± 6.33 
DEXA Results   
Area (cm2) 2272.36 ± 204.07 
Bone Mineral Content (BMC) (g) 2809.40 ± 496.03 
Bone Mass Density (g/cm2) 1.23 ± 0.12 
T-score 0.47 ± 1.16 
Z-score 0.69 ± 1.00 
Fat Mass (g) 43269.77 ± 14496.35 
Lean Mass (g) 61955.47 ± 9977.11 
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Lean + BMC (g) 64764.87 ± 10360.97 
Total Mass (g) 108034.61 ± 17846.39 
% Fat 39.46 ± 8.46 
% Fat Percentile Youth Normal 83.68 ± 14.78 
% Fat Percentile Age Matched 70.23 ± 20.53 
Blood Markers   
WBC (x103/uL) 6.66 ± 1.79 
RBC (x106/uL) 4.60 ± 0.39 
Hemoglobin (g/dL) 13.40 ± 1.17 
Hematocrit (%) 161.75 ± 71.97 
Platelets (x103/uL) 266.75 ± 48.10 
Glucose Serum (mg/dL) 93.83 ± 9.56 
Creatinine (mg/dL) 1.53 ± 3.31 
Total Cholesterol (mg/dL) 179.17 ± 30.46 
Triglycerides (mg/dL) 120.38 ± 42.61 
HDL (mg/dL) 53.21 ± 13.48 
VLDL (mg/mL) 24.08 ± 8.59 
LDL (mg/mL) 61.58 ± 28.18 
AST (IU/L) 21.29 ± 9.86 
ALT (IU/L) 21.54 ± 14.19 
INR 1.13 ± 0.19 
Prothrombin Time (sec) 11.73 ± 1.94 
aPTT (sec) 29.22 ± 3.38 
Apolipoprotein A-1 (mg/dL) 154.83 ± 24.75 
Apolipoprotein B (mg/dL) 44.50 ± 20.07 
Apo B/A-1 ratio 0.58 ± 0.18 
Bilirubin, total (mg/dL) 0.49 ± 0.25 
GGT (IU/L) 28.79 ± 24.46 
 
Correlations  
Many values reached significance, which was determined at the 
conventional p=0.05 level. Correlations were considered as strong when the 
correlation coefficient is > 0.40 and moderate when it is > 0.22. As expected, 
many characteristics were correlated relating to weight parameters.  For 
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example, BMI positively correlated with iliac WC (r=0.888, p<0.001), smallest WC 
(r=0.848; p<0.001), and broadest hip WC (r=0.954; p<0.001). Additionally, BMI 
showed strong positive correlations with weight (r=0.853; p<0.001), % fat 
percentile youth normal (YN) (r=0.608; p<0.005), % fat percentile age matched 
(AM) (r=0.767; p<0.001), fat mass (r=0.953; p<0.001), and % fat (r=0.759; 
p<0.001). Weight reached similar significance with the aforementioned 
parameters, but additionally positively correlated with lean mass (r=0.570; 
p<0.01), bone mineral content (BMC) (r=0.444; p<0.05), and bone mass density 
(BMD) (r=0.502; p<0.05). Height reached even greater significance in positive 
correlations with BMC (r=0.876; p<0.01, BMD (r=0.769; p<0.01) and lean mass 
(r=0.817; p<0.01), in addition to a strong positive correlation with area (cm2) 
(r=0.911; p<0.01). A positive correlation was seen between age and % fat 
percentile AM (r=0.431; p<0.05). As anticipated, % fat inversely correlated with 
lean mass (r=-0.465; p<0.05) and lean mass + BMC (r=-0.465; p<0.05). 
Analyzing the baseline variables assessed by the CANTAB testing, a 
positive correlation was noted between IED total stages completed and weight 
(p=0.436; p<0.05), lean mass (r=0.465; p<0.05), and lean mass+ BMC (r=0.463; 
p<0.05). Adversely, total errors made in IED inversely correlated with those same 
parameters (r=-0.449, r=-0.473, r=-0.471; p<0.05, p<0.05, p<0.05, respectively).  
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DISCUSSION 
 
Through assessing extensive baseline parameters, a cohort of controls 
has been assembled to compare against one week (short-term) and one month 
(long-term) effects of lorcaserin via fMRI, neurocognitive testing, anthropometric 
measurements and hormonal changes, thereby strengthening our study’s internal 
validity. Although no significant novel findings were brought to light through 
baseline data analysis, it was both important and interesting to compare all 
variables for potential correlations. Many of the parameters that reached 
significance confirmed expected correlations. For example, BMI exhibited strong 
positive correlations (p<0.01) with the majority of the variables related to being 
overweight: all three WC measurements, weight, all three % fat variables, and fat 
mass. As BMI is a measure of weight divided by height squared, this would make 
sense for these variables to correlate strongly. As weight exhibited these similar 
aforementioned correlations but with the additional positive correlations of DEXA-
assessed lean mass (p<0.01), BMC (p<0.05) and BMD (p<0.05), we concluded 
that the weight of muscle bone was accounted for in these correlations, 
explaining the difference in statistical significance between BMI and weight. Also 
as expected, % fat showed a negative correlation lean mass (r=-0.465; p<0.05) 
and lean + BMC (r=-0.465; p<0.05), all three parameters assessed by the DEXA 
scan. This makes logical sense, as the more lean mass one has, the less fat 
mass they would be expected to have, and vice versa.  
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With regards to the CANTAB tests, the most significant findings were 
positive correlations between IED stages and weight (p=0.436; p<0.05), lean 
mass (r=0.465; p<0.05), and lean mass+ BMC (r=0.463; p<0.05), suggesting that 
an increase in one’s lean mass could result in an increased number of IED total 
stages completed or vice versa. Simultaneously, inverse correlations were 
observed between total errors made in IED and the same said variables 
(p<0.05), confirming that an increase in lean mass was associated with fewer 
errors and, hence, more total stages completed. Whether this was coincidental or 
causal, further analysis would need to be expanded upon with a range of BMI 
populations, since all subjects in the study were obese. Muscle mass as a 
component of lean mass and weight (rather than fat-related variables) could 
possibly explain differences in these correlations. One potential source for this 
relationship could stem from differences within the obese population in exercise, 
as many studies have shown exercise’s potential to improve cognition (Napoli et 
al., 2014; Sommer & Kahn, 2015). Therefore, physical activity or another factor 
that could potentially affect maintenance, shifting and flexibility of attention, as is 
assessed through the IED task, should be investigated in future studies.  
Although no significant correlations were observed with the baseline SST, 
it must be taken into account that all of the baseline subjects are obese and, 
therefore, there was not a control lean population with which to compare many of 
these task performances, in contrast to other studies that had shown such 
altered activity in obese as compared to lean populations (Batterink et al., 2010; 
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Davis et al., 2004; Hendrick et al., 2012; Ryden et al., 2003). Likewise, even 
though there were no correlations seen with VRM, administering the 
neurocognitive tasks during future visits will serve to compare against baseline 
results and see whether weight loss as a result of lorcaserin, in conjunction with 
dieting, will show improvements in verbal recall performance as shown in past 
studies (Kretsch et al., 1997). Therefore, again, a reference point has been 
established for each subject in order to determine if lorcaserin exhibits any 
effects on improving cognitive task performance. 
As the study is still ongoing, the remainder of the baseline data will be 
obtained when the rest of the 40 subjects have also completed their visit 1. 
Additionally, due to the double-blind nature of the study, all 40 subjects need to 
complete their visit 4 before the study can be unblinded as to whether each 
participant was receiving lorcaserin or placebo. At that point, baseline visit 1 
values can be compared to those of visit 4, after treatment of lorcaserin or 
placebo, and the obtained p-values can be analyzed for comparison. Therefore, 
currently, it is not possible to make any assumptions about who received which 
medication and how it would affect their physical health characteristics as 
assessed in the Results section.  
In conclusion, it is anticipated that the mechanisms that lorcaserin enacts 
in the CNS in mediation of appetite can be further elucidated. As the study 
progresses, it is likely that changes will be observed in the areas of the brain 
involved in food cravings, eating disinhibitions, and other hedonic aspects of food 
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consumption, such as the insular cortex,	  medial OFC and striatum (Stoeckel et 
al., 2009). Decreased activity in these areas would be expected with treatment of 
lorcaserin in comparison to placebo. Other changes include increased activation 
in lateral aspects of the PFC and anterior cingulate cortex, as assessed by 
viewing food and non-food imagery after one week and one month of treatment 
with lorcaserin or placebo (Hare et al., 2009). Significant differences in the BOLD 
signals produced by the reward systems while on treatment as compared to 
placebo are expected, possibly as a result of agonistic activation of the 
melanocortin-4 receptor pathway, which will optimistically decrease food intake 
(Benoit et al., 2000). Therefore, changes in VAS hunger assessment, where 
lorcaserin would enhance feelings of satiety, while decreasing food consumption 
desires associated with reward processing activation should also be seen. 
Overall, the findings thus far are consistent with numerous other studies involving 
obese populations and, as the study progresses, pioneering and exciting results 
should be obtained. 
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